HC Wainwright & Co. Maintains Buy on NRX Pharmaceuticals, Raises Price Target to $45
Benzinga Newsdesk 8 months ago
NewsPrice TargetAnalyst Ratings
HC Wainwright & Co. analyst Patrick R. Trucchio maintains NRX Pharmaceuticals (NASDAQ:NRXP) with a Buy and raises the price target from $40 to $45.
HC Wainwright & Co. analyst Patrick R. Trucchio maintains NRX Pharmaceuticals (NASDAQ:NRXP) with a Buy and raises the price target from $40 to $45.